Conference report: 4th Anglo-Swedish medicinal chemistry symposium

Future Medicinal Chemistry

Volumn 1, Issue 3, 2009, Pages 431-434

  Hall, Adrian ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 8 AZA QUINAZOLINE; ADENOSINE TRIPHOSPHATASE; G PROTEIN COUPLED RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; KU 00673794; LY 2216684; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PF 232798; PF 994888; PHOSPHOTRANSFERASE; UK 432097; UNCLASSIFIED DRUG; VER 53116; VER 55192; CHEMOKINE RECEPTOR CCR5; ENZYME; ENZYME INHIBITOR; GLYCINE TRANSPORTER; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MEDICAL RESEARCH; NEOPLASM; PRIORITY JOURNAL; TISSUE DISTRIBUTION; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; SWEDEN;

CHEMISTRY, PHARMACEUTICAL; ENZYME INHIBITORS; ENZYMES; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, CCR5; RECEPTORS, G-PROTEIN-COUPLED; SWEDEN; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES;

EID: 77953441994     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.42     Document Type: Conference Paper

References (8)

1. Brough PA, Aherne W, Barril X et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51, 196-218 (2008).
2. Angell RA, Aston NM, Bamborough P et al. Biphenyl amide p38 kinase inhibitors 3: improvement of cellular and in vivo activity. Bioorg. Med. Chem. Lett. 18, 4428-4432 (2008).
3. Ahmad S, Madsen CS, Stein PD et al. (3R,5S,E)-7- (4-(4-fluorophenyl)-6- isopropyl-2-(methyl(1- methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5- yl)-3,5-dihydroxyhept-6-enoic Acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibitor with reduced myotoxicity potential. J. Med. Chem. 51, 2722-2733 (2008).
4. Pinard E, Ceccarelli SM, Stalder H, Alberati D. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 16, 349-353 (2006).
5. Pinard E, Alberati D, Borroni E et al. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 18, 5134-5139 (2008).
6. Hall A, Billinton A, Brown SH et al. Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)- methyl]oxy}phenyl)methyl]-2- pyridinecarboxylate (GSK269984A) an EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg. Med. Chem. Lett. 19, 2599-2603 (2009).
7. Price DA, Armour D, de Groot M et al. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett. 17, 4633-4637 (2007).
8. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Disc. 6 881-890 (2007).